Singapore, July 10 -- China-based CStone Pharmaceuticals has announced an exclusive partnership with Istituto Gentili, a leading European biopharmaceutical company with a century-long heritage in oncology, to commercialise sugemalimab across Western Europe and the UK.

Under the terms of the agreement, Gentili will receive exclusive commercialisation rights for sugemalimab in 23 European countries-including 18 EEA countries (Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece , Ireland, Italy, Liechtenstein, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, and Sweden)-as well as the United Kingdom, Andorra, Monaco, San Marino, and Vatican City.

CStone is eligible to receive up to $192.5 million in total consid...